James I. Geller, MD
An improved understanding of pediatric non-brain rhabdoid tumors will not only improve outcomes for this patient population, but could aid in progress for other malignancies, explained James I. Geller, MD.
“There's so much to learn about cancer in general by looking at these rare cancers,” said Geller. “Treating them will benefit not just the [pediatric patients], but others. They really do provide an opportunity for our field to move forward in broad ways.”
Pediatric non-brain rhabdoid tumors account for approximately 30 cases in the United States annually. Work is ongoing to find targetable abnormalities and more effective treatment options for these patients, Geller added.
... to read the full story